Interim Report fourth Quarter and full year 2020
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“STENOCARE”) today announces its unaudited results for the period 01.01.2020 – 31.12.2020. The report is attached to this release and is also available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
“Despite the continued challenges caused by Covid19 STENOCARE was able to return to having medical cannabis products for sale in Sweden in the fourth quarter of 2020. This was important for several reasons: We entered a new country, started generating revenue and is was proof of our ability to execute on the STENOCARE 2.0 strategy”.
| (KDKK) |
01.10.2020 31.12.2020 3 months |
01.10.2019 31.12.2019 3 months |
01.01.2020 31.12.2020 12 months |
01.01.2019 31.12.2019 12 months |
| Total income *) | 105 | 11,255 | 198 | 16,206 |
| Net sales | 105 | 0 | 198 | 4,942 |
| Operating profit before depreciation (EBITDA) | -3,845 | 7,313 | -11,831 | 4,417 |
| Net financial items | -11 | -485 | -1,648 | -2,112 |
| Result per share (DKK) | -0.34 | 0.59 | -1.12 | 0.19 |
| Solidity (%) | 93 | 43 | 93 | 43 |
Result per share: The result for the period divided by the average number of shares. Total number of shares as of December 31, 2020, amounted to 11,676,126 (8,942,762). Average number of shares for the fourth quarter 2020 was 11,676,126 (8,942,762).
Solidity: Equity divided by total capital.
*Total income includes net sales and other income.
Highlights during the period
- December 2020, STENOCARE announced the first delivery of THC medical cannabis oil products to Swedish patients
- December 2020, the company shared the decision from The U.N. to reclassify cannabis as a less dangerous drug
Highlights after the period
- February 2021, STENOCARE announced the first delivery of THC-CBD balanced medical cannabis oil products to Swedish patients
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on February 25, 2021.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.